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Background: Bacterial infections account for most peritoneal dialysis (PD)-associated peritonitis episodes. However,
anaerobic PD peritonitis is extremely rare and intuitively associated with intra-abdominal lesions. In this study, we
examined the clinical characteristics of PD patients who developed anaerobic peritonitis.
Methods: We retrospectively identified all anaerobic PD peritonitis episodes from a prospectively collected PD
registry at a single center between 1990 and 2010. Only patients receiving more than 3 months of PD were
enrolled. We analyzed clinical features as well as outcomes of anaerobic PD peritonitis patients.
Results: Among 6 patients, 10 episodes of PD-associated peritonitis were caused by anaerobic pathogens (1.59% of
all peritonitis episodes during study the period), in which the cultures from 5 episodes had mixed growth.
Bacteroides fragilis was the most common species identified (4 isolates). Only 3 episodes were associated with
gastrointestinal lesions, and 4 episodes were related to a break in sterility during exchange procedures. All
anaerobic pathogens were susceptible to clindamycin and metronidazole, but penicillin resistance was noted in 4
isolates. Ampicillin/sulbactam resistance was found in 2 isolates. In 5 episodes, a primary response was achieved
using the first-generation cephalosporin and ceftazidime or aminoglycoside. In 3 episodes, the first-generation
cephalosporin was replaced with aminoglycosides. Tenckhoff catheter removal was necessary in 2 episodes. Only
one episode ended with mortality (due to a perforated bowel).
Conclusion: Anaerobic PD-associated peritonitis might be predominantly caused by contamination, rather than
intra-abdominal events. Half of anaerobic PD-associated peritonitis episodes had polymicrobial growth. The overall
outcome of anaerobic peritonitis is fair, with a high catheter survival rate.
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Peritoneal dialysis (PD)-associated peritonitis is an im-
portant contributor to morbidity and mortality, account-
ing for one-fifth to one-third of technique failures in PD
practice [1,2]. Among all, Gram-positive bacteria consti-
tute the most frequently isolated pathogens (45–65%),
followed by Gram-negative bacteria (25–40%) and fungi
(3–6%) [1-4]. Infection with mycobacteria and anaerobic
bacteria is rare, both of which are found in <0.5% of
peritonitis episodes [1].* Correspondence: 007378@ntuh.gov.tw
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reproduction in any medium, provided the orAlthough anaerobic bacteria significantly outnumber
other Gram-negative bacteria in the normal flora of the
gastrointestinal (GI) tract, they have surprisingly weak
pathogenicity as compared with other species [5]. Con-
sequently, researchers place less focus on anaerobic bac-
teria. Furthermore, complicated methods for culturing
these bacteria hamper the accurate identification of
these pathogens [6]. However, anaerobic bacteria assume
an increasingly important role by causing infections
among immunocompromised hosts, including end-stage
renal disease (ESRD) patients on dialysis [7].
ESRD patients acquire anaerobic infections mostly from
hematogenous spread of GI sources or rarely, from denti-
tion defects [5,8-10], but these scenarios are common only
in those receiving hemodialysis. Anaerobic infections intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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PD peritonitis. According to the International Society for
Peritoneal Dialysis (ISPD) guidelines, anaerobic PD-
associated peritonitis episodes are discussed mainly within
the polymicrobial peritonitis section, and surgical inter-
ventions are recommended if anaerobic pathogens coexist
with other enteric microorganisms [11-13]. However, not
all anaerobic PD-associated peritonitis episodes occur with
intra-abdominal catastrophe. Issues pertaining to periton-
itis from a single anaerobic pathogen also remain unex-
plored, and reports on anaerobic PD-associated peritonitis
are extremely sparse. Therefore, the current study ana-
lyzed the clinical features and outcomes of anaerobic PD-
associated peritonitis in our center.
Methods
Study design and setting
This was a retrospective analysis of a prospectively col-
lected cohort in the National Taiwan University Hospital
(NTUH) PD program. In our PD registry, all patients with
ESRD initiated on PD or initially on hemodialysis but later
switched to PD in our institute were identified, and entered
into our PD registry. Only patients under maintenance PD
for more than 3 months were eligible in the current study.
We identified all episodes of culture-confirmed anaerobic
peritonitis between 1990 and 2010. Peritonitis was diag-
nosed according to the presence of peritoneal signs and
cloudy effluent with leukocyte counts >100/μL and >50%
neutrophils. Relapse peritonitis was defined as peritonitis
recurring within 4 weeks after the treatment of previous
episodes involving the same pathogens, while repeat peri-
tonitis was defined as peritonitis recurring after 4 weeks of
previous episodes involving the same pathogens [11,12].
Clinical data collection
We reviewed all PD patients’ demographic profiles, which
included age, gender, and comorbidities such as diabetes
mellitus (DM), hypertension, coronary artery disease
(CAD), congestive heart failure (CHF), peripheral artery
occlusive disease, and previous malignancy. Past experi-
ences of admission and surgeries were also recorded.
For each anaerobic peritonitis episode, we recorded the
PD vintage, modality (continuous ambulatory peritoneal
dialysis [CAPD] or automated peritoneal dialysis [APD]),
initial symptoms, most recent serum biochemistry profiles,
blood leukocyte counts/C-reactive protein (CRP) levels
during peritonitis episodes, pathogens identification results
(cultures and/or Gram stain), and antibiograms. The pre-
sumed etiology of peritonitis included a break in sterility
during the exchange procedures, GI flora translocation,
major intra-abdominal events (including diverticulitis or
perforated viscera), and undetermined. Patients with peri-
tonitis were initially treated with empirical intraperitoneal
cefazolin/aminoglycoside or cefazolin/ceftazidime (after1998, due to concerns of aminoglycoside impairing residual
renal function) according to ISPD recommendations
[11-13], unless otherwise clinically indicated.
Outcome variables
Outcome measures included primary response, antibiotic
switch (secondary response), relapse peritonitis, repeat peri-
tonitis, Tenckhoff catheter removal, and mortality. The pri-
mary response was defined as symptomatic improvement
with effluent leukocyte counts <100/μL within 3 days under
the first-line antibiotics. The secondary response was de-
fined as a response to next-line antibiotics when effluent
failed to clear with the first-line antibiotics [11-13].
Ethical considerations
The ethics committee of the NTUH approved this study
(NO. 201212165RINC). The local institutional review
board did not mandate patient consent, since no inter-
ventions were performed, and patient privacy was not
breached.
Results
During the study period, a total of 328 patients received
PD therapy in our institute for 35,211 patient-months, and
the overall peritonitis rate was 1 per 56.2 patient-months.
Among the 627 episodes of PD peritonitis, 6 patients de-
veloped 10 episodes caused by anaerobic pathogens (1.59%
of all episodes). One patient developed 4 episodes within
3 years separately; another developed 2 episodes within
4 years; and the remaining patients each had 1 episode.
Clinical features of patients with anaerobic PD peritonitis
Among these patients who developed anaerobic PD peri-
tonitis, two-thirds of them were women, and the mean
age was 46 years (range, 20–68 years). The mean patient
vintage at the time of anaerobic PD peritonitis was
50 months (range, 5–109 months). Their comorbidities
were as follows: five patients (83%) had hypertension,
three patients (50%) had CHF and coronary artery dis-
ease (CAD), one patient (17%) had systemic lupus
erythematosus and was receiving azathioprine; still an-
other (17%) had a history of peptic ulcers. Past admis-
sion history included cystoscopy examination (one
patient; 17%) and lupus flare-up (one patient; 17%). No
patient ever received intra-abdominal surgery before.
The most common primary causes of ESRD were
chronic glomerulonephritis (3 patients), followed by DM
(1 patient), lupus nephritis (1 patient), and Chinese herb
nephropathy (1 patient).
One patient was receiving intravenous cefepime for
hospital-acquired pneumonia before index peritonitis,
while 2 patients were given intraperitoneal vancomycin
and ceftazidime for preceding PD peritonitis weeks ago.
No patient had recently undergone GI endoscopy. The
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(within one month) were provided in Table 1.Clinical courses of anaerobic PD peritonitis
The most common presenting symptoms were abdominal
pain (8 episodes), followed by rebounding tenderness (6 ep-
isodes), fever (4 episodes), nausea/vomiting (3 episodes),
diarrhea (1 episode), and loss of consciousness (1 episode).
All patients had turbid dialysate. The initial blood leukocyte
levels were 10,245/μL (range 5850–19,980/μL), with 84.2%
neutrophils. The average CRP levels at presentation were
10.5 (range 0.61-29.7 mg/dL). Mean effluent leukocyte
counts were 1978/μL (range 100–9000/μL), with 83.3%
neutrophils.
Effluent Gram stain only identified Gram positive bacilli
in one episode. Effluent cultures revealed Bacteroides
fragilis in 4 episodes, Lactobacillus species in 3 episodes,
Bacteroides thetaiotaomicron in 2 episodes, and Peptos-
treptococcus species in 1 episode. Half of the episodes
showed polymicrobial growth, in which Bacteroides and
Lactobacillus species were present in 4 and 1 episodes of
mixed growth, respectively. The other organisms cultured
were Enterococcus species, Klebsiella pneumoniae, and
Pseudomonas aeruginosa as well as Candida albicans.
None of them had concomitant bacteremia, and no pa-
tient had concomitant extra-gastrointestinal infection foci
(including respiratory tracts).
Contrary to previous reports [11,12], the most common
cause of anaerobic peritonitis was associated with sterility
break (4 cases with a relevant history of contamination
during exchange procedures). Structural GI lesions were
identified in 2 episodes. One had diverticulitis, and the
other was suspected to have small bowel perforation. One
case resulted from GI flora translocation presenting as
diarrhea for days before peritonitis. No obvious explana-
tions were discovered in the remaining 3 episodes of an-
aerobic peritonitis.
The antibiotic susceptibilities of the anaerobic pathogens
are shown in Table 2. All anaerobic isolates were suscep-
tible to metronidazole and clindamycin. The rate of resist-
ance to penicillin was the highest (4 isolates), followed by
cefmetazole (3 isolates) and flomoxef (2 isolates). Resist-
ance to beta-lactam/beta-lactamase inhibitors (ampicillin/Table 1 The most recent serum biochemical profiles of
patients before anaerobic PD peritonitis episodes
Variables Average Range
Hemoglobin (g/dL) 9.8 7.7-11.4
Albumin (mg/dL) 3.6 2.4-4.7
Creatinine (mg/dL) 9.0 5.7-12.3
Total cholesterol (mg/dL) 218 104-296sulbactam) was present in 2 isolates. One isolate showed
intermediate resistance to cefmetazole.Clinical outcomes of anaerobic PD peritonitis
Table 3 displays the outcomes of patients with anaerobic
PD peritonitis. For the first-line antibiotics, intraperitoneal
cefazolin/ceftazidime was used in 5 episodes, while intra-
peritoneal cefazolin/tobramycin was used in 3 episodes
(all before 1998). Two patients were given intravenous
vancomycin/meropenem and imipenem/cilastatin with
amphotericin B to cover potential nosocomial pathogens.
A primary response was achieved in 5 episodes, and a sec-
ondary response occurred after antibiotic switching,
from intraperitoneal cefazolin/ceftazidime to ceftazidime/
amikacin or gentamicin in 3 episodes. Tenckhoff catheter
removal was necessary in 2 patients because of refractory
peritonitis, even under intravenous vancomycin/mero-
penem and imipenem/cilastatin. One patient was later
switched to hemodialysis, and the other died of intestinal
perforation 1 month later, considering that surgical inter-
vention was unsuitable because of the patient’s poor
condition. Those who responded to antibiotics were
maintained on antibiotics for a total of 14 days. There
was no relapse or repeat peritonitis after anaerobic PD
peritonitis episodes.Discussion
In the present case series, Bacteroides species were the
most common anaerobic organisms identified from PD-
associated peritonitis patients, and half of the episodes were
accompanied by other enteric pathogens. Only 2 episodes
were associated with proven GI lesions. All isolates showed
100% susceptibility to metronidazole and clindamycin. The
overall outcome was fair with 80% antibiotic cure rate, 20%
Tenckhoff catheter loss, and 10% mortality from index peri-
tonitis episodes.
Anaerobic bacteria account for a substantial minority
of PD-associated peritonitis episodes, and most reports
on PD-associated peritonitis did not address this issue
[14,15]. Therefore, a dedicated description of anaerobic
peritonitis features is lacking in the literature. In the
ANZDATA registry, anaerobic peritonitis accounted for
only 0.1% of single-pathogen peritonitis over a 6-year
period, rising to 1.1% if only polymicrobial episodes are
considered [1]. In the United States and Canada, anaer-
obic peritonitis constitutes <1% of all episodes [2]. In
our experience, anaerobic pathogens were causative in
1.59% of all peritonitis episodes, which was higher than
other reports. A lower peritonitis incidence of other
pathogens might underscore the percentage of anaerobic
episodes in our PD patients. On the other hand, this
might reflect the geographic or ethnic difference in host
Table 2 Antibiotic susceptibility of anaerobic pathogens
of peritonitis episodes (n = 10)
Antibiotics Susceptible Intermediate Resistant Not tested
Cefmetazole 4 1 2 3
Chloramphenicol 7 0 0 3
Clindamycin 7 0 0 3
Flomoxef 5 0 2 3
Metronidazole 7 0 0 3
Penicillin 3 0 4 3
Ampicillin/
sulbactam
5 1 1 3
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[16]. Nonetheless, the lower peritonitis incidence in our
cohort suggests that our cases need to be interpreted in
light of our institutional characteristics and the potential
generalizability.
In the ISPD guidelines, anaerobic growth is frequently
linked to intra-abdominal events requiring surgical at-
tention [11,12] because delayed intervention could be
detrimental [17,18]. However, in our case series, only 2
episodes had GI lesions identified. All 3 patients with
GI-related etiologies had polymicrobial growth, and
Bacteroides species were the main pathogens (3 epi-
sodes); while in contamination cases, Lactobacillus spe-
cies were the predominant organisms isolated (3 episodes),
followed by Bacteroides thetaiotaomicron (1 episode). In
addition, one case of contamination also showed poly-
microbial growth. From these data, it might be plausible
that anaerobic peritonitis could be further divided into
2 categories, contamination-related or intra-abdominal
event-related. Each might be featured by different anaerobic
species (Lactobacillus vs. Bacteroides). Consequently, we
postulate that neither the growth of anaerobic pathogens
from effluent nor polymicrobial growth serves as a token
for intra-abdominal events. It might be better to considerTable 3 Clinical courses and outcomes of anaerobic peritoniti
Offending pathogens First-line antibiotics
Patient 1 Bacteroides thetaiotaomicron IP cefazolin/ceftazidime
Patient 2 Bacteroides fragilis IV vancomycin/meropene
Patient 3 Lactobacillus IP cefazolin/ceftazidime
Bacteroides thetaiotaomicron IP cefazolin/ceftazidime
Lactobacillus IP cefazolin/ceftazidime
Bacteroides fragilis IV imipenem/amphotericin
Patient 4 Lactobacillus IP cefazolin/ceftazidime
Patient 5 Bacteroides fragilis IP cefazolin/tobramycin
Peptostreptococcus IP cefazolin/tobramycin
Patient 6 Bacteroides fragilis IP cefazolin/tobramycin
Abbreviations: IP intraperitoneal; IV intravenous.failure of technique sterility simultaneously to avoid un-
necessary examinations or even operations.
In the previous reports of anaerobic infections, Bac-
teroides species were most commonly isolated, followed by
Clostridium and Peptostreptococcus species [19,20]. Risk
factors for anaerobic infection include male gender, ad-
vanced age, presence of cancer, DM, chronic obstructive
pulmonary disease, liver diseases, heart diseases, and GI
surgeries [19,21]. However, in our patients, only 10–20%
had these predisposing factors. As we identified, a potential
factor associated with anaerobic peritonitis in PD patients
might be a recent exposure to antibiotics (3 episodes). It is
then likely that PD patients with anaerobic peritonitis
might bear different clinical features than the general
population.
The choice of antibiotics in anaerobic PD-associated
peritonitis has not been specifically addressed previously,
and the ISPD guidelines have not included a section fo-
cused on anaerobic peritonitis [11,12]. For anaerobic path-
ogens, aminoglycosides have counteractive effects against
earlier microbial pathogenicity, while clindamycin protects
hosts from abscess formation [20]. The resistance rates for
anaerobic pathogens among available reports are as follows:
penicillin, approximately 30–60%; metronidazole, <5%;
clindamycin, 6–38%; beta-lactam/beta-lactamase inhibitors,
5–15%; and cephamycin, 10–40% [5,19,20,22]. All the an-
aerobic isolates in our patients were susceptible to metro-
nidazole and clindamycin, while 20–30% of cases were
resistant to cephamycin and ampicillin/sulbactam. An in-
teresting finding is that 50% of our cases responded well
to cefazolin/ceftazidime, although these antibiotics are
reported to have poor efficacy against anaerobes, while
aminoglycosides retain their efficacy because of earlier use
during disease courses, as stated above [5,20,23]. Several
studies have demonstrated that empirical cefazolin/
ceftazidime could be effective against mixed infections.
These antibiotics could reverse the favorable locals episodes (n = 10)
Antibiotics switch Outcomes
IP ceftazidime/amikacin Cure
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negative aerobes [24,25]. From this view, 3 out of 5
polymicrobial anaerobic peritonitis episodes in our pa-
tients are responsive to cefazolin/ceftazidime use, and
these antibiotics might exert an indirect effect of anti-
anaerobics. Based upon our limited experience in the
current case series, we proposed that first-line antibiotics
with metronidazole or clindamycin could be rational for
anaerobic PD peritonitis, especially for single anaerobic
episodes. Past studies also concurred that clindamycin
might be be useful for patients allergic to penicillin, with
Gram-positive coverage requirements[26].
The presence of comorbidities and isolates of Bacteroides,
Clostridium, or polymicrobial infections raises the risk of
adverse outcomes in anaerobic infections [19,20]. In the
ANZDATA registry, catheter removal was necessary in
100% of anaerobic peritonitis episodes, and 90% of cases re-
quired hospitalization [1]. However, their case number was
only 5. Our findings suggested that the catheter outcome of
anaerobic peritonitis was not as poor as previous studies
showed (20% catheter loss; Table 3). This difference in out-
come could be attributed to contamination as the most
common cause of anaerobic peritonitis in this study, and
early effective antibiotics could salvage the catheter. This
was quite different from worse outcomes of patients with
intra-abdominal events related to anaerobic peritonitis.
Moreover, no repeat or relapse peritonitis episode was ob-
served. In our limited experience, anaerobic PD-associated
peritonitis patients showed a 10% mortality rate (Table 3).
This high mortality rate, compared with <4% mortality with
other pathogens [1,2], could be the result of intra-
abdominal catastrophe rather than anaerobic peritonitis
per se. Consequently, we suggest that anaerobic periton-
itis might still carry a favorable outcome if no intra-
abdominal events occur.Limitations
Our study had several limitations. First, the case num-
ber (6 patients, 10 episodes) was low, and could not per-
mit detailed analysis of the clinical features and courses
of anaerobic PD peritonitis. Second, our current experi-
ences in managing anaerobic PD peritonitis were pre-
liminary, and should not be considered the norm for
these rare patients. Third, one patient in our series de-
veloped 4 times of anaerobic peritonitis, and thus might
weigh more than other enrollees. Fourth, Chinese herb
nephropathy is rare in Western countries, and whether
this ESRD etiology could correlate with anaerobic periton-
itis is unclear. Nonetheless, the fair outcome of these
anaerobic PD peritonitis patients is interesting and
warrants our attention. Further larger studies are
needed to better guide clinicians in treating anaerobic
PD peritonitis patients.Conclusion
Anaerobic peritonitis is very rare among all PD-associated
peritonitis episodes, and Bacteroides species is the most
common causative agent. Although polymicrobial infec-
tions occur in half of the episodes, contamination is still the
single predominant etiology of anaerobic peritonitis. The
overall outcome is fair if no intra-abdominal events occur,
with only 20% of patients experiencing catheter loss.
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